Eli Lilly was founded in 1876, with Headquarters located in Indianapolis, Indiana, U.S.A and with operations based in the US and EU, Eli Lilly is now the 15th largest pharmaceutical company in the world. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs.
Eli Lilly is a research-based pharmaceutical company committed to create value for all stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients and to help people live longer, healthier, more active lives. Eli Lilly employs approximately 41,000 people worldwide. Approximately 9,000 employees are engaged in research and development. Clinical research is being conducted in more than 55 countries, with research and development facilities located in 6 countries and manufacturing plants located in 13 countries. Lilly products are marketed in 120 countries.
Our tasks
in the project
Lilly will be active in all sections of the project, but one, i.e., WP1, WP2, WP3, WP4, WP5, WP6, and WP7.
Our contribution to the project
The Lilly team have significant experience and expertise in both regulatory affairs as well as delivery of innovative IT/Digital solutions and services including web sites, click to chat, chatbots, SMS and social media. A relevant service is ‘lillymedical.com’ providing medical answers online.
A TASTE OF OUR WORK
Lilly is an active partner in many IMI1 and IMI2 initiatives, such as IMI2 projects DO-IT (Big Data for better outcomes, policy innovation and healthcare system transformation) and EHDEN (European Health Data and Evidence Network). Also, in IMI1 EHR4CR (Electronic Health Records Systems for Clinical Research).
Eli Lilly and Company: A Spirit of Discovery
